Jan Philipp Bewersdorf

List of Publications by Year
in descending order

95	1,495	304368	414034
papers	citations	22 h-index	32 g-index

95	95	95	1712
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A review of FLT3 inhibitors in acute myeloid leukemia. Blood Reviews, 2022, 52, 100905.	2.8	50
2	Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment?. Expert Review of Anticancer Therapy, 2022, , 1-3.	1.1	2
3	Azacitidine maintenance in AML post induction and posttransplant. Current Opinion in Hematology, 2022, 29, 84-91.	1.2	3
4	Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals of Hematology, 2022, 101, 557-569.	0.8	44
5	Gilteritinib clinical activity in relapsed/refractory <scp>FLT3</scp> mutated <scp>acute myeloid leukemia</scp> previously treated with <scp>FLT3</scp> inhibitors. American Journal of Hematology, 2022, 97, 322-328.	2.0	21
6	Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood, 2022, 139, 1766-1770.	0.6	4
7	Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes and Development, 2022, 36, 259-277.	2.7	19
8	Outcomes of <scp>TP53</scp>â€mutated <scp>AML</scp> with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American Journal of Hematology, 2022, 97, .	2.0	24
9	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood, 2022, 140, 285-289.	0.6	15
10	Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?. Cancers, 2022, 14, 2434.	1.7	7
11	Racial disparities in patients with TP53 mutated acute myeloid leukemia.. Journal of Clinical Oncology, 2022, 40, e19007-e19007.	0.8	0
12	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leukemia and Lymphoma, 2021, 62, 1195-1202.	0.6	5
13	Interferon alpha therapy in essential thrombocythemia and polycythemia veraâ€"a systematic review and meta-analysis. Leukemia, 2021, 35, 1643-1660.	3.3	29
14	Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews, 2021, 45, 100709.	2.8	24
15	Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management and Research, 2021, Volume 13, 645-657.	0.9	5
16	Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?. Expert Review of Hematology, 2021, 14, 199-210.	1.0	5
17	Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases. Journal of Thrombosis and Thrombolysis, 2021, 52, 854-862.	1.0	1
18	Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. Best Practice and Research in Clinical Haematology, 2021, 34, 101245.	0.7	8

#	Article	IF	Citations
19	Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Cancers, 2021, 13, 1610.	1.7	17
20	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia and Lymphoma, 2021, 62, 1-10.	0.6	0
21	The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era. Expert Review of Anticancer Therapy, 2021, 21, 989-1002.	1.1	2
22	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e483-e487.	0.2	1
23	Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2021, 39, 7045-7045.	0.8	0
24	BiTEs, DARTS, BiKEs and TriKEsâ€"Are Antibody Based Therapies Changing the Future Treatment of AML?. Life, 2021, 11, 465.	1.1	21
25	Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia. Oncotarget, 2021, 12, 1314-1317.	0.8	1
26	Maintenance therapies in acute myeloid leukemia. Current Opinion in Oncology, 2021, Publish Ahead of Print, 658-669.	1.1	3
27	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 3394-3401.	0.6	17
28	Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Advances, 2021, 5, 4686-4690.	2.5	4
29	Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantationâ€"A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2021, 27, 997.e1-997.e11.	0.6	20
30	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosisâ€"A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2021, 27, 873.e1-873.e13.	0.6	9
31	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic Advances in Hematology, 2021, 12, 204062072110434.	1.1	3
32	Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting. Blood, 2021, 138, 3701-3701.	0.6	0
33	The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia. Hemato, 2021, 2, 748-763.	0.2	2
34	Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica, 2020, 105, 102-111.	1.7	31
35	Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia and Lymphoma, 2020, 61, 397-408.	0.6	19
36	The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Reviews, 2020, 40, 100639.	2.8	15

#	Article	IF	Citations
37	The minimal that kills: Why defining and targeting measurable residual disease is the â€œSine Qua Nonâ€• for further progress in management of acute myeloid leukemia. Blood Reviews, 2020, 43, 100650.	2.8	17
38	Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. Leukemia and Lymphoma, 2020, 61, 1178-1187.	0.6	15
39	Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?. Cells, 2020, 9, 2310.	1.8	37
40	No child with a transfusion-dependent haemoglobinopathy left unchelated: are we there yet?. Lancet Haematology,the, 2020, 7, e429-e430.	2.2	0
41	Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era. Expert Review of Hematology, 2020, 13, 1189-1199.	1.0	0
42	Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic Advances in Hematology, 2020, 11, 204062072095500.	1.1	19
43	Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes. Cancer, 2020, 126, 4664-4667.	2.0	0
44	Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemiaâ€”A systematic review and metaâ€analysis. Transfusion, 2020, 60, 2360-2369.	0.8	32
45	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	2.2	56
46	Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. Expert Review of Hematology, 2020, 13, 1131-1142.	1.0	8
47	A complex karyotype and a genetic mutation in acute myeloid leukaemia. Lancet, The, 2020, 396, 2018.	6.3	0
48	Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?. Best Practice and Research in Clinical Haematology, 2020, 33, 101222.	0.7	9
49	Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia and Lymphoma, 2020, 61, 2180-2190.	0.6	24
50	Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?. Leukemia and Lymphoma, 2020, 61, 2295-2312.	0.6	7
51	Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e712-e723.	0.2	12
52	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances, 2020, 4, 2192-2201.	2.5	68
53	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia, 2020, 34, 3149-3160.	3.3	54
54	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia and Lymphoma, 2020, 61, 1220-1225.	0.6	15

#	Article	IF	Citations
55	Evolving therapies for lower-risk myelodysplastic syndromes. Annals of Hematology, 2020, 99, 677-692.	0.8	16
56	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia and Lymphoma, 2020, 61, 1455-1464.	0.6	4
57	Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review of Hematology, 2020, 13, 489-499.	1.0	24
58	Isolated trisomy 11 in patients with acute myeloid leukemia â€“ is the prognosis not as grim as previously thought?*. Leukemia and Lymphoma, 2020, 61, 2254-2257.	0.6	1
59	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances, 2020, 4, 1615-1623.	2.5	32
60	Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica, 2020, 105, 2659-2663.	1.7	66
61	Prognostic Models in Myelodysplastic Syndromes. , 2020, , 109-127.		2
62	Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis. Blood, 2020, 136, 34-35.	0.6	5
63	Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood, 2020, 136, 13-14.	0.6	10
64	Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.. Journal of Clinical Oncology, 2020, 38, e19057-e19057.	0.8	0
65	Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis. Drugs of Today, 2020, 56, 755.	0.7	1
66	Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. Blood, 2020, 136, 5-7.	0.6	1
67	Clinical Characteristics and Outcomes of Splenic Infarction in Cancer Patients - a Retrospective, Single Center Report of 206 Cases. Blood, 2020, 136, 22-23.	0.6	0
68	Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes. Blood, 2020, 136, 2-3.	0.6	1
69	Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. Blood, 2020, 136, 21-22.	0.6	1
70	Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood, 2020, 136, 44-45.	0.6	0
71	Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171). Blood, 2020, 136, 1-1.	0.6	3
72	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. Blood Reviews, 2019, 37, 100587.	2.8	23

#	Article	IF	Citations
73	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A populationâ€level analysis. Cancer, 2019, 125, 4241-4251.	2.0	28
74	Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Review of Anticancer Therapy, 2019, 19, 717-729.	1.1	12
75	Calcium Influx through Plasma-Membrane Nanoruptures Drives Axon Degeneration in a Model of Multiple Sclerosis. Neuron, 2019, 101, 615-624.e5.	3.8	63
76	One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Expert Review of Hematology, 2019, 12, 575-578.	1.0	4
77	Healthcare expenses for treatment of acute myeloid leukemia. Expert Review of Hematology, 2019, 12, 641-650.	1.0	14
78	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Review of Anticancer Therapy, 2019, 19, 393-404.	1.1	26
79	Transforming growth factor (TGF)-Î² pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia, 2019, 33, 1303-1312.	3.3	43
80	Getting personal with myelodysplastic syndromes: is now the right time?. Expert Review of Hematology, 2019, 12, 215-224.	1.0	9
81	Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. Therapeutic Advances in Hematology, 2019, 10, 204062071881669.	1.1	71
82	Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis . Cancer Management and Research, 2019, Volume 11, 10777-10790.	0.9	32
83	Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?. Leukemia and Lymphoma, 2019, 60, 1354-1369.	0.6	23
84	Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?. Blood Reviews, 2019, 34, 67-83.	2.8	80
85	Challenges in HSV encephalitis: normocellular CSF, unremarkable CCT, and atypical MRI findings. Infection, 2019, 47, 267-273.	2.3	26
86	Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study. Blood, 2019, 134, 116-116.	0.6	1
87	Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience. Blood, 2019, 134, 5173-5173.	0.6	1
88	Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States. Blood, 2019, 134, 646-646.	0.6	7
89	Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience. Blood, 2019, 134, 1330-1330.	0.6	4
90	Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?. Blood, 2019, 134, 5174-5174.	0.6	0

#	Article	IF	Citations
91	Novel and preclinical treatment strategies in pneumococcal meningitis. Current Opinion in Infectious Diseases, 2018, 31, 85-92.	1.3	12
92	Mast Cells Are Activated by Streptococcus pneumoniae In Vitro but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection In Vivo. Frontiers in Immunology, 2018, 9, 550.	2.2	9
93	The SPEED (sepsis patient evaluation in the emergency department) score: a risk stratification and outcome prediction tool. European Journal of Emergency Medicine, 2017, 24, 170-175.	0.5	23
94	Early and aggressive ISR with a polymer- and carrier-free drug-coated stent system. Indian Heart Journal, 2017, 69, 651-654.	0.2	4
95	Generic atorvastatin is as effective as the brand-name drug (LIPITORÂ®) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Research Notes, 2017, 10, 291.	0.6	9